Tag: life sciences
-
Quick Crispr-Based Test Detects Malaria in Blood
A blood test designed for low-resource field settings is shown to quickly detect and distinguish between different malaria parasites needed to accurately diagnose the disease.
-
Skeletal Stem Cells Enhanced for Bone Repair
Researchers in the U.K. created a bandage with enhanced human skeletal stem cells that in lab mice repairs simulated skull defects.
-
Cancer Screening Analytics Company Acquired in $8B Deal
A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock.
-
Mental Health Drug Company Raises $127.5M in IPO
A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer.
-
Point-of-Care Covid-19 Diagnostic Shows High Accuracy
A test for SARS-CoV-2 viruses in humans is shown in field tests to return diagnostic results in 90 minutes with accuracy comparable to the gold-standard RT-PCR test.
-
Wearable Device Shown to Relieve Migraine Pain
Evidence collected from electronic neuro-stimulation devices shows for most people the wearable systems relieve migraine pain without other drugs.
-
Biotechs Partner on Gene-Editing Cystic Fibrosis Therapy
Two biotechnology companies are adding to their current collaboration to develop delivery techniques for gene-editing treatments for cystic fibrosis.
-
Early Trial Results Show Antibody Treating Covid-19
First results from a clinical trial testing an experimental synthetic antibody, show patients receiving the therapy at a specific dosage, cleared their SARS-CoV-2 viruses within 11 days.
-
Precision Cancer Therapy Start-Up Gains $110M in Early Funds
A company creating cancer therapies with individualized engineered T-cells is raising $110 million in its first venture funding round.
-
Gilead Acquires Cancer Therapy Biotech for $21B
Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion.